| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. | N Engl J Med | 2009 | 5.79 |
| 2 | Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. | Clin Cancer Res | 2008 | 2.06 |
| 3 | Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. | Proc Natl Acad Sci U S A | 2010 | 1.67 |
| 4 | Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. | Clin Cancer Res | 2008 | 1.66 |
| 5 | Platelet-rich plasma: quantification of growth factor levels and the effect on growth and differentiation of rat bone marrow cells. | Tissue Eng | 2006 | 1.60 |